Genzyme Corporation (NASDAQ: GENZ) today announced that it has detected a virus that impairs cell growth in one of six bioreactors at its Allston Landing manufacturing facility. The company has decided to temporarily interrupt bulk production at the plant to sanitize the facility. Genzyme is collaborating with regulatory agencies as...
treatment News
ATLANTA, GA – GeoVax Labs Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the closure of patient enrollment for the Phase 1/2 clinical study evaluating Gedeptin® in patients suffering from advanced head and neck cancer. Kelly McKee, MD, MPH, GeoVax’s Chief Medical Officer,...
Waltham, MA – A small study of 15 patients published Thursday in The New England Journal of Medicine provides strong evidence of the therapeutic potential of CD19 CAR-T therapies in autoimmune disorders. The study, conducted in Germany, enrolled patients who had been diagnosed with systemic lupus erythematosus (SLE), idiopathic inflammatory...
FOSTER CITY, Calif. – Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology in a paper entitled, “Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or...
Arlington, Texas – A multidisciplinary team of researchers that included 14 graduate students from The University of Texas at Arlington has created a new framework to provide optimal personalized treatment options for individuals with esophageal cancer. “Esophageal cancer is an unusually diverse disease with many heterogeneities and cancerous origins, which...
BUFFALO, NY – A new research paper was published in Oncotarget’s Volume 14, entitled, “The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies.” To evade cell cycle controls, malignant cells rely upon rapid expression of...
BUFFALO, NY- March 4, 2024 – A new research paper was published in Oncotarget’s Volume 15 on February 22, 2024, entitled, “Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.” Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed...
FOSTER CITY, Calif. — Gilead Sciences, Inc., today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC...
Givinostat halted muscle shrinkage and fat infiltration in men with Becker muscular dystrophy (BMD) despite failing to ease muscle scarring, compared to a placebo, according to top-line, one-year results of an ongoing Phase 2 clinical trial. “We are very encouraged by the significant difference in muscle fat infiltration between the two groups after...
AMSTERDAM, The Netherlands — Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today new data showing that a one-time administration of its lead product GlyberaTM results in significant long-term health benefits. Long-term follow-up data from two clinical trials show that one administration with...